Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis - PubMed (original) (raw)

. 1989 Jun;261(24):3561-6.

Affiliations

• PMID: 2542633

Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis

M T Grattan et al. JAMA. 1989 Jun.

Abstract

We studied the effects of cytomegalovirus (CMV) infection on 301 cardiac transplant recipients who were treated during the cyclosporine era of immunosuppression (1980 to the present). These patients received varying combinations of cyclosporine, azathioprine, prednisone, rabbit antithymocyte globulin, and OKT3 as their immunosuppressive therapy. Two hundred ten patients were free of CMV infection (non-CMV group). During the same period CMV infection developed in 91 patients, as manifested by a fourfold IgG serologic titer rise, demonstration of CMV inclusion bodies in tissue, or positive cultures for the virus (CMV group). The rate of graft rejection was significantly higher in the CMV group. Graft atherosclerosis was significantly more severe in the CMV group as judged by angiographic criteria or by pathologic study. Patient survival rates were significantly lower in the CMV group. Death caused by graft atherosclerosis was significantly more common among patients in the CMV group. Finally, the graft loss rate (from either death or retransplantation for atherosclerosis) was significantly greater in the CMV group. These data demonstrate that CMV infection in cardiac transplant recipients is associated with more frequent rejection, graft atherosclerosis, and death.

PubMed Disclaimer

Similar articles

• The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients.
  Lewis RM, Johnson PC, Golden D, Van Buren CT, Kerman RH, Kahan BD. Lewis RM, et al. Transplantation. 1988 Feb;45(2):353-9. doi: 10.1097/00007890-198802000-00022. Transplantation. 1988. PMID: 2830686
• Cytomegalovirus infection associated accelerated heart allograft arteriosclerosis may impair the late function of the graft.
  Koskinen P, Lemstrøm K, Mattila S, Häyry P, Nieminen MS. Koskinen P, et al. Clin Transplant. 1996 Dec;10(6 Pt 1):487-93. Clin Transplant. 1996. PMID: 8996768
• Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation.
  Cooper DK, Novitzky D, Schlegel V, Muchmore JS, Cucchiara A, Zuhdi N. Cooper DK, et al. J Heart Lung Transplant. 1991 Sep-Oct;10(5 Pt 1):656-62; discussion 662-3. J Heart Lung Transplant. 1991. PMID: 1659901
• Cytomegalovirus and chronic allograft rejection in liver transplantation.
  Gao LH, Zheng SS. Gao LH, et al. World J Gastroenterol. 2004 Jul 1;10(13):1857-61. doi: 10.3748/wjg.v10.i13.1857. World J Gastroenterol. 2004. PMID: 15222023 Free PMC article. Review.
• Angiographic implications of cardiac transplantation.
  Alderman EL, Wexler L. Alderman EL, et al. Am J Cardiol. 1989 Sep 5;64(9):16E-21E. doi: 10.1016/0002-9149(89)90729-7. Am J Cardiol. 1989. PMID: 2672763 Review.

Cited by

• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
  Vernooij RW, Michael M, Ladhani M, Webster AC, Strippoli GF, Craig JC, Hodson EM. Vernooij RW, et al. Cochrane Database Syst Rev. 2024 May 3;5(5):CD003774. doi: 10.1002/14651858.CD003774.pub5. Cochrane Database Syst Rev. 2024. PMID: 38700045 Review.
• Cardiac Allograft Vasculopathy: Challenges and Advances in Invasive and Non-Invasive Diagnostic Modalities.
  Kamel MA, Scalia IG, Badr AT, Baba Ali N, Farina JM, Pereyra M, Abbas MT, Mahmoud AK, Scott RL, Steidley DE, Rosenthal JL, Lemond LM, Sell-Dottin KA, Hardaway BW, Barry T, Yang M, Chao CJ, Jokerst CE, Ayoub C, Arsanjani R. Kamel MA, et al. J Cardiovasc Dev Dis. 2024 Mar 21;11(3):95. doi: 10.3390/jcdd11030095. J Cardiovasc Dev Dis. 2024. PMID: 38535118 Free PMC article. Review.
• Proximity-dependent mapping of the HCMV US28 interactome identifies RhoGEF signaling as a requirement for efficient viral reactivation.
  Medica S, Crawford LB, Denton M, Min CK, Jones TA, Alexander T, Parkins CJ, Diggins NL, Streblow GJ, Mayo AT, Kreklywich CN, Smith P, Jeng S, McWeeney S, Hancock MH, Yurochko A, Cohen MS, Caposio P, Streblow DN. Medica S, et al. PLoS Pathog. 2023 Oct 2;19(10):e1011682. doi: 10.1371/journal.ppat.1011682. eCollection 2023 Oct. PLoS Pathog. 2023. PMID: 37782657 Free PMC article.
• Advancing Precision Medicine in Myocarditis: Current Status and Future Perspectives in Endomyocardial Biopsy-Based Diagnostics and Therapeutic Approaches.
  Baumeier C, Harms D, Aleshcheva G, Gross U, Escher F, Schultheiss HP. Baumeier C, et al. J Clin Med. 2023 Jul 31;12(15):5050. doi: 10.3390/jcm12155050. J Clin Med. 2023. PMID: 37568452 Free PMC article. Review.
• Multicenter study of universal prophylaxis versus pre-emptive therapy for patients at intermediate risk (R+) for CMV following heart transplantation.
  Lerman JB, Green CL, Molina MR, Maharaj V, Ortega-Legaspi JM, Sen S, Flattery M, Maziarz EK, Shah KB, Martin CM, Alexy T, Shah P, Morris AA, DeVore AD, Cole RT. Lerman JB, et al. Clin Transplant. 2023 Oct;37(10):e15065. doi: 10.1111/ctr.15065. Epub 2023 Jul 1. Clin Transplant. 2023. PMID: 37392192 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information